XBiotech Inc., a pre-market biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company's lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases. XBiotech, Inc. was founded in 2005 and is headquartered in Austin, Texas.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:XBIT
CUSIPN/A
Phone512-386-2900
Debt
Debt-to-Equity RatioN/A
Current Ratio12.24
Quick Ratio12.24
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.70 per share
Price / Book2.65
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-33,150,000.00
Net MarginsN/A
Return on Equity-41.50%
Return on Assets-39.43%
Miscellaneous
Employees51
Outstanding Shares35,520,000
XBiotech (NASDAQ:XBIT) Frequently Asked Questions
What is XBiotech's stock symbol?
XBiotech trades on the NASDAQ under the ticker symbol "XBIT."
How were XBiotech's earnings last quarter?
XBiotech Inc (NASDAQ:XBIT) announced its earnings results on Monday, November, 14th. The biopharmaceutical company reported ($0.38) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.46) by $0.08. View XBiotech's Earnings History.
When is XBiotech's next earnings date?
Who are some of XBiotech's key competitors?
Some companies that are related to XBiotech include Viking Therapeutics (VKTX), Progenics Pharmaceuticals (PGNX), Akebia Therapeutics (AKBA), Kura Oncology (KURA), Aclaris Therapeutics (ACRS), ChemoCentryx (CCXI), Keryx Biopharmaceuticals (KERX), Beyondspring (BYSI), Five Prime Therapeutics (FPRX), Prothena (PRTA), Insys Therapeutics (INSY), Lannett (LCI), Cara Therapeutics (CARA), Stemline Therapeutics (STML) and TIGENIX/S (TIG).
Who are XBiotech's key executives?
XBiotech's management team includes the folowing people:
- Mr. John Simard, Founder, Pres, CEO & Chairman (Age 56)
- Ms. Queena Han, VP of Fin. & HR and Sec. (Age 51)
- Mr. Benjamín Guzmán, Sr. VP of Corp. Strategy & Fin. (Age 62)
- Dr. Sushma Shivaswamy Ph.D., Chief Scientific Officer (Age 40)
- Mr. Trey Benson, Commercial Head
When did XBiotech IPO?
(XBIT) raised $76 million in an IPO on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $18.00-$20.00 per share. WR Hambrecht + Co served as the underwriter for the IPO.
Has XBiotech been receiving favorable news coverage?
Media stories about XBIT stock have been trending positive on Wednesday, according to Accern Sentiment Analysis. The research group identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. XBiotech earned a media sentiment score of 0.43 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 48.26 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
Who are XBiotech's major shareholders?
Which major investors are buying XBiotech stock?
How do I buy shares of XBiotech?
Shares of XBIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is XBiotech's stock price today?
One share of XBIT stock can currently be purchased for approximately $4.50.
How big of a company is XBiotech?
XBiotech has a market capitalization of $160.19 million. XBiotech employs 51 workers across the globe.
How can I contact XBiotech?
XBiotech's mailing address is 8201 E. RIVERSIDE DRIVE BUILDING 4 SUITE 100, AUSTIN TX, 78744. The biopharmaceutical company can be reached via phone at 512-386-2900 or via email at [email protected]
MarketBeat Community Rating for XBiotech (XBIT)
MarketBeat's community ratings are surveys of what our community members think about XBiotech and other stocks. Vote "Outperform" if you believe XBIT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XBIT will underperform the S&P 500 over the long term. You may vote once every thirty days.
